Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a Monday note.

The investment firm said in the research note that HMB-002 is particularly well suited for Type 1 patients, who comprise about 75% of the diagnosed Von Willebrand disease population, because it targets restoration of the underlying von Willebrand factor.

The analysts noted that HMB-002 has demonstrated encouraging preliminary clinical efficacy, with eight of nine evaluable patients experiencing no treated bleeding events during the 28 days following a single dose.

Multidose Part B data expected in late 2026 or early 2027 should provide the first assessment of whether the early efficacy observations translate into durable bleed reduction with chronic dosing, according to the note.

Wedbush reiterated its outperform rating and $55 price target on the stock.

Shares of Hemab were up 2% in Monday trading.

Price: 38.79, Change: +0.75, Percent Change: +1.99